Adrenocortical secondary prevention: Difference between revisions
(Created page with "_NOTOC_ {{CMG}}; {{AR}} {{MAD}} {{Adrenocortical carcinoma secondary prevention}} -Overview- Patients should be followed at 3-month intervals after initial treatment for 2 to...") |
No edit summary |
||
| Line 1: | Line 1: | ||
__NOTOC__ | |||
{{CMG}}; {{AR}} {{MAD}} | {{CMG}}; {{AR}} {{MAD}} | ||
{{Adrenocortical carcinoma secondary prevention}} | {{Adrenocortical carcinoma secondary prevention}} | ||
==Overview== | |||
Patients should be followed at 3-month intervals after initial treatment for 2 to 3 years and surveillance intervals may be increased to 6 months for the next 5 years. Surveillance includes cross-sectional imaging of chest, abdomen, and pelvis, the use of FDG-PET for lesions of an unclear nature, laboratory evaluation for steroid hormones and evaluation of side effects in case of adjuvant mitotane therapy. | Patients should be followed at 3-month intervals after initial treatment for 2 to 3 years and surveillance intervals may be increased to 6 months for the next 5 years. Surveillance includes cross-sectional imaging of chest, abdomen, and pelvis, the use of FDG-PET for lesions of an unclear nature, laboratory evaluation for steroid hormones and evaluation of side effects in case of adjuvant mitotane therapy. | ||
==Adrenocortical carcinoma secondary prevention== | |||
Patients should be followed at 3-month intervals after initial treatment for 2 to 3 years. | Patients should be followed at 3-month intervals after initial treatment for 2 to 3 years. | ||
Surveillance intervals may be increased to 6 months for the next 5 years. | Surveillance intervals may be increased to 6 months for the next 5 years. | ||
| Line 16: | Line 15: | ||
Evaluation of side effects is also important in case of adjuvant mitotane therapy | Evaluation of side effects is also important in case of adjuvant mitotane therapy | ||
==References== | |||
{{ | {{reflist|2}} | ||
Revision as of 16:50, 3 October 2017
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Template:AR Mohammed Abdelwahed M.D[2] Template:Adrenocortical carcinoma secondary prevention
Overview
Patients should be followed at 3-month intervals after initial treatment for 2 to 3 years and surveillance intervals may be increased to 6 months for the next 5 years. Surveillance includes cross-sectional imaging of chest, abdomen, and pelvis, the use of FDG-PET for lesions of an unclear nature, laboratory evaluation for steroid hormones and evaluation of side effects in case of adjuvant mitotane therapy.
Adrenocortical carcinoma secondary prevention
Patients should be followed at 3-month intervals after initial treatment for 2 to 3 years. Surveillance intervals may be increased to 6 months for the next 5 years. Surveillance should also include: Cross-sectional imaging of chest, abdomen, and pelvis The use of FDG-PET for lesions of an unclear nature Laboratory evaluation for steroid hormones Evaluation of side effects is also important in case of adjuvant mitotane therapy